Shuttle Pharma Files Key Patent For PSMA-Targeted PARP Conjugates In Precision Prostate Cancer Therapy

Shuttle Pharmaceuticals Holdings Inc. is a development and discovery stage pharmaceutical firm specialist in precision cancer therapy announced the submission of patent application documents to the U.S. Patent and Trademark Office for PSMA-targeted PARP inhibitor conjugates. This development utilizes PSMA ligands to guide therapeutic agents to prostate cancer cells therefore focuses on targeted treatment for metastatic castration-resistant prostate cancer (mCRPC).

Anatoly Dritschilo, MD, Shuttle Pharma’s Chairman and Chief Scientific Officer, said in a statement, “I believe a significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment. The Shuttle Pharma scientists have collaborated with Dr. Kozikowski on discovery projects for radiation-sensitizing drugs and have recently focused on the discovery of novel PSMA ligands with the intent of targeting prostate cancer cells preferentially to the effects of radiation and chemotherapeutic agents. We look forward to the continued advancement of our Shuttle Diagnostics’ subsidiary and the opportunity to develop a theranostic that has the potential to play a significant role in the future diagnosis and treatment of prostate cancer.”

The patent is rooted upon Shuttle’s collaboration with Dr. Alan Kozikowski, a significant figure in medicinal chemistry whose prior work helped lead to the development of Pylarify and Pluvitco, two key PSMA-targeted agents. Unlike traditional antibody-drug conjugates, the smaller PSMA-targeting ligands offer potential advantages for more efficient drug delivery, which could revolutionize prostate cancer treatment by reducing off-target toxicity and enhancing treatment efficacy. 

The company division is also working on predictive tests for radiation therapy outcomes and diagnostics using PSMA-B ligands. There is currently a lack of available tests to predict the success of specific treatments in prostate cancer. Given the projected growth of the PSMA PET Imaging and radiopharmaceutical market, Shuttle Pharma’s advancements could place the company in a strong position within a field balanced to reach multi-billion-dollar valuations by 2030.